natgillin/translations-raw huggingface dataset:
The mean volume of distribution following a single intraveneous dose of rasagiline is 243 l.
Povprečni volumen porazdelitve, ki sledi enkratnemu intravenskemu odmerku 14 razagilina, je 243 l.
Plasma protein binding following a single oral dose of 14C-labelled rasagiline is approximately 60 to 70%.
Plazemska proteinska vezava, ki sledi enojnemu odmerku s C- označenim razagilinom, je približno 60 do 70%.
The metabolism of rasagiline proceeds through two main pathways:
Presnova razagilina poteka preko dveh glavnih poti:
N-dealkylation and/ or hydroxylation to yield:
N- dealkilacije in/ ali hidroksilacije do presnovkov:
1-Aminoindan, 3-hydroxy-N-propargyl-1 aminoindan and 3-hydroxy-1-aminoindan.
1- aminoindana, 3 - hidroksi- N- propargil- 1 aminoindana in 3- hidroksi- 1- aminoindana.
Excretion:
14 Izločanje:
After oral administration of 14C-labelled rasagiline, elimination occurred primarily via urine (62.6%) and secondarily via faeces (21.8%), with a total recovery of 84.4% of the dose over a period of 38 days.
Po peroralni uporabi s C- označenim razagilinom nastopi izločanje v glavnem preko urina (62, 6%) in sekundarno preko blata (21, 8%), s celotnim izločanjem 84, 4% odmerka v 38 dnevih.
Linearity/ non-linearity:
Linearnost/ ne- linearnost:
Rasagiline pharmacokinetics are linear with dose over the range of 0.5-2 mg.
Farmakokinetika razagilina je linearna pri odmerkih od 0, 5 do 2 mg.
Its terminal half-life is 0.6-2 hours.
Njegov končni razpolovni čas je 0, 6 do 2 uri.
Patients with hepatic impairment:
Bolniki z jetrnimi okvarami:
In subjects with mild hepatic impairment, AUC and Cmax were increased by 80% and 38%, respectively.
38%.
In subjects with moderate hepatic impairment, AUC and Cmax were increased by 568% and 83%, respectively (see section 4.4).
Pri osebah z zmernimi jetrnimi okvarami, sta AUC in Cmax porasla za 568% in 83% (glejte poglavje 4. 4).
Rasagiline's pharmacokinetics characteristics in subjects with mild (CLcr 50-80 ml/ min) and moderate (CLcr 30-49 ml/ min) renal impairment were similar to healthy subjects.
Farmakokinetične lastnosti razagilina so bile pri osebah z blago (očistek kreatinina (CLcr) 50 – 80 ml/ min) in zmerno (CLcr 30 – 49 ml/ min) podobne kot pri zdravih osebah.
Rasagiline was not carcinogenic in rats at systemic exposure, 84 – 339 times the expected plasma exposures in humans at 1 mg/ day.
Razagilin pri sistemski izpostavljenosti pri podganah, ki je bila 84 do 339- kratna pričakovana plazemska izpostava pri človeku pri 1 mg/ dan, ni bil kancerogen.
In mice, increased incidences of combined bronchiolar/ alveolar adenoma and/ or carcinoma were observed at systemic exposures, 144 - 213 times the expected plasma exposure in humans at 1 mg/ day.
Pri miših so pri sistemski izpostavljenosti, ki je bila 144 do 213- kratna pričakovana plazemska izpostava pri človeku pri
Mannitol Maize starch Pregelatinised maize starch Colloidal anhydrous silica Stearic acid Talc
manitol koruzni škrob želatiniran koruzni škrob brezvodni koloidni silicijev dioksid stearinska kislina smukec
3 years Bottles:
3 leta Plastenka:
Aluminium/ aluminium blister packs of 7, 10, 28, 30, 100 or 112 tablets.
Pretisni omoti: aluminij/ aluminij pretisni omoti po 7, 10, 28, 30, 100 ali 112 tablet.
White, high-density polyethylene bottle with or without a child-resistant cap containing 30 tablets.
Plastenka: bela plastenka iz polietilena visoke gostote, z ali brez za otroke varnim pokrovčkom, vsebuje 30 tablet.
Teva Pharma GmbH Kandelstr 10 D-79199 Kirchzarten Germany
Teva Pharma GmBH Kandelstr 10 D- 79199 Kirchzarten Nemčija
21/ 02/ 2005
8 21/ 02/ 2005
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
10 A IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
Computerweg 10 3542 DR Utrecht THE NETHERLANDS
Computerweg 10 3542 DR Utrecht NIZOZEMSKA
13 PARTICULARS TO APPEAR ON THE OUTER PACKAGING (CARTON FOR BLISTER PACK)
13 PODATKI NA ZUNANJI OVOJNINI (ŠKATLA ZA PRETISNI OMOT)
7, 10, 28, 30, 100, 112 tablets
7, 10, 28, 30, 100, 112 tablet
Teva Pharma GmbH D-79199 Kirchzarten, Germany
Teva Pharma GmbH D- 79199 Kirchzarten, Nemčija
15 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
15 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
16 PARTICULARS TO APPEAR ON THE OUTER PACKAGING (CARTON FOR BOTTLE) PARTICULARS TO APPEAR ON THE BOTTLE LABEL
16 PODATKI NA ZUNANJI OVOJNINI (ŠKATLA ZA PLASTENKO) PODATKI NA NALEPKI NA PLASTENKI
AZILECT 1 mg tablets Rasagiline
AZILECT 1 mg tablete razagilin
What AZILECT is and what it is used for 2.
Kaj je zdravilo AZILECT in za kaj ga uporabljamo 2.
Before you take AZILECT 3.
Kaj morate vedeti, preden boste vzeli zdravilo AZILECT 3.
How to take AZILECT 4.
Kako jemati zdravilo AZILECT 4.
How to store AZILECT 6.
Shranjevanje zdravila AZILECT 6.
AZILECT is used for the treatment of Parkinson’ s disease as monotherapy (without levodopa) or as adjunct therapy (with levodopa).
AZILECT se uporablja v zdravljenju Parkinsonove bolezni kot monoterapija (brez levodope) ali kot dodatna terapija (z levodopo).
In Parkinson’ s disease there is a loss of cells producing dopamine in certain areas in the brain.
V Parkinsonovi bolezni nastopi izguba celic, ki v določenih možganskih področjih tvorijo dopamin.
AZILECT enables increased and sustained levels of dopamine in these areas.
AZILECT omogoča povišanje in vzdrževanje ravni dopamina v teh predelih.
BEFORE YOU TAKE AZILECT
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO AZILECT
Do not take AZILECT
Ne jemljite zdravila AZILECT:
- if you are allergic (hypersensitive) to rasagiline or any of the other ingredients of AZILECT.
- če ste alergični na (preobčutljivi za) razagilin ali katerokoli sestavino zdravila AZILECT,
- if you have a severe liver insufficiency.
- če imate hudo jetrno okvaro.
John's Wort), while taking AZILECT.
Ne jemljite inhibitorjev monoaminooksidaze (MAO), ki se lahko uporabljajo kot antidepresivi ali pa kot zdravila za zdravljenje Parkinsonove bolezni ali pa za katerokoli drugo indikacijo (vključno z zdravili ali naravnimi pripravki brez recepta kot je npr. šentjanževka), medtem ko jemljete AZILECT.
Do not take the strong pain killer, pethidine, while taking AZILECT.
Ne jemljite močnih zdravil proti bolečinam, kot je petidin, medtem ko jemljete AZILECT.
You should wait at least 14 days after stopping AZILECT treatment and starting treatment with MAO inhibitors or pethidine.
Ko prenehate zdravljenje z zdravilom AZILECT morate počakati najmanj 14 dni, preden začnete zdravljenje z MAO inhibitorji ali petidinom.
Take special care with AZILECT
Bodite posebno pozorni pri uporabi zdravila AZILECT
- if you have mild to moderate liver insufficiency
- če imate blago do zmerno jetrno okvaro,
- if you take medicines containing fluoxetine, fluvoxamine, dextromethorphan or
- če jemljete zdravila, ki vsebujejo fluoksetin, fluvoksamin, dekstrometorfan ali
sympathomimetics, please see section "Taking other medicines"
simpatikomimetike, prosimo poglejte poglavje » Jemanje drugih zdravil «.
20 The following medicines require specific medical advice before being taken together with AZILECT:
20 Jemanje drugih zdravil Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Certain antidepressants (selective serotonin reuptake inhibitors, tricyclic or tetracyclic antidepressants), the antibiotic ciprofloxacin used against infections, the cough suppressant dextromethorphan, sympathomimetics such as those present in nasal and oral decongestants and cold medications containing ephedrine or pseudoephedrine.
Pri naslednjih zdravilih je pred začetkom jemanja sočasno z zdravilom AZILECT potreben poseben zdravniški nasvet: določeni antidepresivi (selektivni inhibitorji ponovnega privzema serotonina, triciklični ali tetraciklični antidepresivi), antibiotik ciprofloksacin, ki se uporablja proti infekcijam, zdravilo za pomirjanje kašlja dekstrometorfan, simpatikomimetiki, kot so tisti, ki so prisotni v nazalnih ali peroralnih dekongestivih in zdravila proti prehladu, ki vsebujejo efedrin ali psevdoefedrin.
You should wait at least five weeks after stopping fluoxetine treatment and starting treatment with AZILECT.
Po prenehanju jemanja fluoksetina morate počakati najmanj pet tednov, preden pričnete zdravljenje z zdravilom AZILECT.
You should wait at least 14 days after stopping AZILECT treatment and starting treatment with fluoxetine or fluvoxamine.
Po prenehanju jemanja zdravila AZILECT morate počakati najmanj 14 dni, preden pričnete zdravljenje s fluoksetinom ali fluvoksaminom.
Taking AZILECT with food and drink AZILECT may be taken with or without food.
Jemanje zdravila AZILECT skupaj s hrano in pijačo AZILECT lahko jemljete bodisi s hrano bodisi brez nje.
Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine.
Posvetujte se z zdravnikom ali s farmacevtom, preden vzamete katerokoli zdravilo.
Driving and using machines No studies on the effects on the ability to drive and use machines have been performed.
Vpliv na sposobnost upravljanja vozil in strojev Študij, ki bi preučevale učinke na zmožnost vožnje in uporabo strojev, niso izvedli.
HOW TO TAKE AZILECT
KAKO JEMATI ZDRAVILO AZILECT
The usual dose of AZILECT is one tablet of 1 mg taken orally once daily.
Običajni odmerek zdravila AZILECT je ena tableta po 1 mg peroralno enkrat dnevno.
Take the AZILECT carton/ bottle with you to show the doctor or pharmacist.
S seboj vzemite škatlo/ plastenko zdravila AZILECT, da jo boste lahko pokazali svojemu zdravniku ali farmacevtu.
Do not take a double dose to make up for a forgotten dose.
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek..
Like all medicines, AZILECT can cause side effects, although not everybody gets them.
Kot vsa zdravila, ima lahko tudi AZILECT neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Very common (more than 10% of the patients):
Zelo pogosti (več kot 10% bolnikov):
Abnormal movements (dyskinesia), headache
Nenavadni gibi (diskinezija), glavobol
Common (between 1-10% of the patients):
Pogosti (med 1- 10% bolnikov):
Abdominal pain, accidental injury (primary falls), allergic reaction, fever, flu syndrome, malaise, neck pain, angina pectoris, low blood pressure when rising to a standing position (postural hypotension), anorexia, constipation, dyspepsia, dry mouth, vomiting, abnormal results of blood tests (leucopenia), joint pain (arthralgia), arthritis, tenosynovitis, weight loss, abnormal dreams, difficulty in muscular co- ordination (ataxia), depression, vertigo, prolonged muscle contractions (dystonia), rhinitis, contact dermatitis, rash, vesiculobullous rash, conjunctivitis, urinary urgency
21 vstajanju iz sedečega v stoječi položaj (posturalna hipotenzija), neješčnost, zaprtje, prebavne motnje, suha usta, bruhanje, abnormni rezultati krvnih preiskav (levkopenija), bolečine v sklepih (artralgija), vnetje sklepov, vnetje kitne ovojnice, izguba telesne mase, nenavadne sanje, težave v mišični koordinaciji (ataksija), depresija, vrtoglavica, podaljšana mišična krčenja (distonija), vnetje nosne sluznice, kontaktni dermatitis, izpuščaj, vezikulobulozni izpuščaj, vnetje veznice, siljenje na uriniranje
Uncommon (between 0.1-1% of the patients):
Občasni (med 0, 1- 1% bolnikov):
Stroke (cerebrovascular accident), myocardial infarct
Kap (možgansko žilni dogodki), miokardni infarkt
In addition, skin cancer was reported in around 1% of patients in the placebo controlled clinical trials.
Prav tako so, pri približno 1% bolnikov v s placebom nadzorovanih kliničnih študijah, poročali o kožnem karcinomu.
Nevertheless, scientific evidence suggests that Parkinson’ s disease, and not any drug in particular, is associated with a higher risk of skin cancer (not exclusively melanoma).
Vendar pa znanstveni dokazi nakazujejo, da je Parkinsonova bolezen, ne pa zdravila sama po sebi, povezana z visokim tveganjem karcinoma kože (ne izključno melanoma).
In post marketing experience these symptoms have also been observed in Parkinson's disease patients treated with AZILECT.
V post- marketinških izkušnjah so prav tako zaznali navedene simptome pri bolnikih s Parkinsonovo boleznijo, ki so bili zdravljeni z zdravilom AZILECT.
HOW TO STORE AZILECT
SHRANJEVANJE ZDRAVILA AZILECT
Store in the original package.
Shranjujete v originalni ovojnini.
What AZILECT contains
Kaj vsebuje zdravilo AZILECT
- The active substance is rasagiline.
- Zdravilna učinkovina je razagilin.
- The other ingredients are mannitol, colloidal anhydrous silica, maize starch, pregelatinised maize
- Pomožne snovi so: manitol, brezvodni koloidni silicijev dioksid, koruzni škrob, želatiniran
starch, stearic acid, talc.
koruzni škrob, stearinska kislina in smukec.
22 AZILECT tablets are presented as white to off-white, round, flat, bevelled tablets, debossed with “ GIL” and “ 1” underneath on one side and plain on the other side.
AZILECT tablete so bele do belkaste, okrogle, ploščate, prirezane tablete z vtisnjenim "GIL" in "1" spodaj na eni strani in brez odtisov na drugi strani.
Marketing Authorisation Holder Teva Pharma GmbH Kandelstrasse 10 D-79199 Kirchzarten Germany
22 Imetnik dovoljenja za promet Teva Pharma GmbH Kandelstrase 10 D- 79199 Kirchzarten Nemčija
Manufacturer Teva Pharmaceuticals Europe B. V.
Izdelovalec Teva Pharmaceuticals Europe B. V.
Computerweg 10 3542 DR Utrecht The Netherlands
Computerweg 10 3542 DR Utrecht Nizozemska
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
Za vse morebitne nadaljnje informacije o tem zdravilu dovoljenja za promet z zdravilom:
It is available as a 5 mg tablet, a 5 mg oral lyophilisate (dispersible tablet), 2.5 mg and 5 mg orodispersible tablets (tablets that dissolve in the mouth), a 0.5 mg/ ml syrup and a 0.5 mg/ ml oral solution.
Na voljo je v obliki 5 mg tablet, 5 mg peroralnega liofilizata (disperzibilna tableta), 2, 5 mg in 5 mg orodisperzibilnih tablet (tablete, ki se raztopijo v ustih), 0, 5 mg/ ml sirupa in 0, 5 mg/ ml peroralne raztopine.
Azomyr is used to relieve the symptoms of allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) or urticaria (a skin condition caused by an allergy, with symptoms including itching and hives).
Zdravilo Azomyr se uporablja za lajšanje simptomov alergijskega rinitisa (vnetja nosne votline, ki ga povzroči alergija, na primer seneni nahod ali alergija na pršice) ali urtikarije (bolezen kože, ki jo povzroča alergija in katere simptomi vključujejo srbenje in izpuščaje).
Azomyr can be taken with or without food.
Zdravilo Azomyr se lahko jemlje s hrano ali brez nje.
The active substance in Azomyr, desloratadine, is an antihistamine.
Zdravilna učinkovina zdravila Azomyr je desloratadin, ki je antihistaminik.
Azomyr has been studied in a total of eight studies involving about 4,800 adult and adolescent patients with allergic rhinitis (including four studies in seasonal allergic rhinitis, and two studies in patients who also had asthma).
Zdravilo Azomyr so raziskali v osmih študijah, ki so vključevale približno 4800 odraslih in mladostnikov z alergijskim rinitisom (vključno s štirimi študijami sezonskega alergijskega rinitisa in dvema študijema pri bolnikih, ki so imeli tudi astmo).
The effectiveness of Azomyr was measured by looking at the change in the symptoms (nasal discharge, itching, sneezing and congestion) before and after two or four weeks of treatment.
Učinkovitost zdravila Azomyr so merili s spremembo simptomov (nabiranje sluzi v nosu, srbenje, kihanje in zamašenost nosu), ki so jih opazovali pred zdravljenjem in dva do štiri tedne po zaključku zdravljenja.
Azomyr has also been studied in 416 patients with urticaria.
Zdravilo Azomyr so raziskali tudi pri 416 bolnikih z urtikarijo.
In all studies, the effectiveness of Azomyr was compared with that of placebo (a dummy treatment).
V vseh študijah so učinkovitost zdravila Azomyr primerjali s placebom (zdravilo brez zdravilne učinkovine).
In allergic rhinitis, looking at the results of all studies taken together, two weeks of treatment with 5 mg Azomyr led to an average decrease in symptom score of 25 to 32%, compared with a decrease of 12 to 26% in the patients receiving placebo.
Dva tedna dolgo zdravljenje z zdravilom Azomyr 5 mg je pri alergijskem rinitisu v vseh študijah skupaj privedlo do povprečnega zmanjšanja števila simptomov za 25 do 32%, v primerjavi z 12 - do 26- odstotnim zmanjšanjem pri bolnikih, ki so prejemali placebo.
In the two studies in urticaria, the decrease in symptom score after six weeks of treatment with Azomyr was 58 and 67%, compared with 40 and 33% in placebo-treated patients.
V dveh študijah pri bolnikih z urtikarijo se je število simptomov po šestih tednih zdravljenja z zdravilom Azomyr zmanjšalo za 58 in 67% v primerjavi s 40 in 33% pri bolnikih, ki so prejemali placebo.
Azomyr should not be used in people who may be hypersensitive (allergic) to desloratadine, loratadine or any of the other ingredients.
Zdravila Azomyr ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) desloratadin, loratadin ali katero koli drugo sestavino zdravila.
The Committee for Medicinal Products for Human Use (CHMP) decided that Azomyr’ s benefits are greater than its risks for the relief of symptoms associated with allergic rhinitis or urticaria.
Odbor za uporabo zdravil v humani medicini (CHMP) je zaključil, da so koristi zdravila Azomyr pri lajšanju simptomov alergijskega rinitisa ali urtikarije večje od z njim povezanih tveganj.
The Committee recommended that Azomyr be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Azomyr odobri dovoljenje za promet.
Other information about Azomyr:
Druge informacije o zdravilu Azomyr:
The European Commission granted a marketing authorisation valid throughout the European Union for Azomyr to SP Europe on 15 January 2001.
Evropska komisija je dovoljenje za promet z zdravilom Azomyr, veljavno po vsej Evropski uniji, odobrila družbi SP Europe dne 15. januarja 2001.
The marketing authorisation was renewed on 15 January 2006.
Dovoljenje za promet z zdravilom je bilo podaljšano 15. januarja 2006.
The full EPAR for Azomyr is available here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Azomyr je na voljo tukaj.
Strength
ovojnina
Pharmaceutical Form
velikost pakiranja
Content
7 tablet
Package size
20 tablet
EU/ 1/ 00/ 157/ 001 EU/ 1/ 00/ 157/ 002 EU/ 1/ 00/ 157/ 003 EU/ 1/ 00/ 157/ 004 EU/ 1/ 00/ 157/ 005 EU/ 1/ 00/ 157/ 006 EU/ 1/ 00/ 157/ 007 EU/ 1/ 00/ 157/ 008 EU/ 1/ 00/ 157/ 009 EU/ 1/ 00/ 157/ 010 EU/ 1/ 00/ 157/ 011 EU/ 1/ 00/ 157/ 012 EU/ 1/ 00/ 157/ 013
EU/ 1/ 00/ 157/ 010
Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr
pretisni omot (Aclar/ PVC, alu)
1 tablet 2 tablets 3 tablets 5 tablets 7 tablets 10 tablets 14 tablets 15 tablets 20 tablets 21 tablets 30 tablets 50 tablets 100 tablets
1 steklenica z 1 merilna žličko
EU/ 1/ 00/ 157/ 014 EU/ 1/ 00/ 157/ 015 EU/ 1/ 00/ 157/ 016 EU/ 1/ 00/ 157/ 017 EU/ 1/ 00/ 157/ 018 EU/ 1/ 00/ 157/ 019 EU/ 1/ 00/ 157/ 020 EU/ 1/ 00/ 157/ 021 EU/ 1/ 00/ 157/ 022 EU/ 1/ 00/ 157/ 023 EU/ 1/ 00/ 157/ 024 EU/ 1/ 00/ 157/ 025 EU/ 1/ 00/ 157/ 026 EU/ 1/ 00/ 157/ 027 EU/ 1/ 00/ 157/ 028 EU/ 1/ 00/ 157/ 029 EU/ 1/ 00/ 157/ 030 EU/ 1/ 00/ 157/ 031
100 ml
Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr
1 steklenica z 1 merilna žličko
0.5 mg/ ml 0.5 mg/ ml 0.5 mg/ ml 0.5 mg/ ml 0.5 mg/ ml 0.5 mg/ ml 0.5 mg/ ml 0.5 mg/ ml 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg
1 steklenica z 1 merilna žličko
Syrup Syrup Syrup Syrup Syrup Syrup Syrup Syrup Oral lyophilisate Oral lyophilisate Oral lyophilisate Oral lyophilisate Oral lyophilisate Oral lyophilisate Oral lyophilisate Oral lyophilisate Oral lyophilisate Oral lyophilisate
0, 5 mg/ ml
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Sirup
bottle (glass) bottle (glass) bottle (glass) bottle (glass) bottle (glass) bottle (glass) bottle (glass) bottle (glass) blister (PVC/ Alu) blister (PVC/ Alu) blister (PVC/ Alu) blister (PVC/ Alu) blister (PVC/ Alu) blister (PVC/ Alu) blister (PVC/ Alu) blister (PVC/ Alu) blister (PVC/ Alu) blister (PVC/ Alu)
Peroralna uporaba
1 bottle with 1 spoon 1 bottle with 1 spoon 1 bottle with 1 spoon 1 bottle with 1 spoon 1 bottle with 1 spoon 1 bottle with 1 spoon 1 bottle with 1 spoon 1 bottle with 1 spoon 1 2 3 5 7 10 14 15 20 21
1 steklenica z 1 merilna žličko
1/ 3 EU/ 1/ 00/ 157/ 032 EU/ 1/ 00/ 157/ 033 EU/ 1/ 00/ 157/ 034 EU/ 1/ 00/ 157/ 035 EU/ 1/ 00/ 157/ 036 EU/ 1/ 00/ 157/ 037 EU/ 1/ 00/ 157/ 038 EU/ 1/ 00/ 157/ 039 EU/ 1/ 00/ 157/ 040 EU/ 1/ 00/ 157/ 041 EU/ 1/ 00/ 157/ 042 EU/ 1/ 00/ 157/ 043 EU/ 1/ 00/ 157/ 044 EU/ 1/ 00/ 157/ 045 EU/ 1/ 00/ 157/ 046 EU/ 1/ 00/ 157/ 047 EU/ 1/ 00/ 157/ 048 EU/ 1/ 00/ 157/ 049 EU/ 1/ 00/ 157/ 050 EU/ 1/ 00/ 157/ 051 EU/ 1/ 00/ 157/ 052 EU/ 1/ 00/ 157/ 053 EU/ 1/ 00/ 157/ 054 EU/ 1/ 00/ 157/ 055 EU/ 1/ 00/ 157/ 056 EU/ 1/ 00/ 157/ 057 EU/ 1/ 00/ 157/ 058
EU/ 1/ 00/ 157/ 022 EU/ 1/ 00/ 157/ 023 EU/ 1/ 00/ 157/ 024 EU/ 1/ 00/ 157/ 025 EU/ 1/ 00/ 157/ 026 EU/ 1/ 00/ 157/ 027 EU/ 1/ 00/ 157/ 028 EU/ 1/ 00/ 157/ 029 EU/ 1/ 00/ 157/ 030 EU/ 1/ 00/ 157/ 031 EU/ 1/ 00/ 157/ 032 EU/ 1/ 00/ 157/ 033 EU/ 1/ 00/ 157/ 034 EU/ 1/ 00/ 157/ 035
Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr
Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr Azomyr
5 mg 5 mg 5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg
5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 5 mg 2, 5 mg
Oral lyophilisate Oral lyophilisate Oral lyophilisate Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet Orodispersible tablet
Peroralni liofilizat Peroralni liofilizat Peroralni liofilizat Peroralni liofilizat Peroralni liofilizat Peroralni liofilizat Peroralni liofilizat Peroralni liofilizat Peroralni liofilizat Peroralni liofilizat Peroralni liofilizat Peroralni liofilizat Peroralni liofilizat Orodisperzibilna tableta
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Peroralna uporaba Peroralna uporaba Peroralna uporaba Peroralna uporaba Peroralna uporaba Peroralna uporaba Peroralna uporaba Peroralna uporaba Peroralna uporaba Peroralna uporaba Peroralna uporaba Peroralna uporaba Peroralna uporaba Peroralna uporaba